Results 141 to 150 of about 5,560 (173)

European Agencies and Input Legitimacy: EFSA, EMeA and EPO in the Post‐Delegation Phase

Journal of European Integration, 2007
Frank Wendler, Susana Borràs
exaly  

Supranational regulatory agencies between independence and control: the EMEA and the authorization of pharmaceuticals in the European Single Market

Journal of European Public Policy, 2007
Thomas Gehring, Sebastian Krapohl
exaly  

Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years

European Journal of Clinical Pharmacology, 2006
Paola Baiardi, Adriana Ceci, Fedele Bonifazi   +2 more
exaly  

Clinical trials for registration in the European Union: the EMEA 5-year experience in oncology

Critical Reviews in Oncology/Hematology, 2002
Spiros Vamvakas
exaly  

EMEA / EFSA / ESCOP

Zeitschrift für Phytotherapie, 2008
openaire   +1 more source

Assessing the Performance of the EMEA’s Centralized Procedure: A Comparative Analysis with the US FDA

Drug Information Journal, 2008
Kenneth Kaitin
exaly  

6th EMEA-IFAPP Conference

International Journal of Pharmaceutical Medicine, 2002
openaire   +2 more sources

Data protection in the EMEA

2020
openaire   +1 more source

Value Chain EMEA – Collecting and Sorting

2022
Jürgen Ephan, Arne Köhne
openaire   +1 more source

Delays in review of fees costs EMEA £2·9 million

Lancet, The, 1998
Arthur Rogers
exaly